| Name | Sorafenib N-Oxide |
|---|---|
| Synonyms |
2-Pyridinecboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide
Sorafenib N-oxide Sorafenib impurities172 4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-Methyl-2-pyridinecboxaMide 1-Oxide Sorafenib impurity 23/Sorafenib N-Oxide/4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-2-(methylcbamoyl)pyridine 1-oxide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-1-oxidopyridin-1-ium-2-carboxamide 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-2-(methylcbamoyl)pyridine 1-oxide Sorafenib Impurity 27(Sorafenib N-Oxide) Sorafenib impurities11 |
| Density | 1.455g/cm3 |
|---|---|
| Boiling Point | 591.655ºC at 760 mmHg |
| Melting Point | 220-222ºC |
| Molecular Formula | C21H13ClD3F3N4O4 |
| Molecular Weight | 483.84300 |
| Flash Point | 311.622ºC |
| Exact Mass | 483.10000 |
| PSA | 104.92000 |
| LogP | 6.12010 |
| Index of Refraction | 1.601 |
|
~55%
583840-03-3 |
| Literature: BAYER CORPORATION Patent: US2003/216446 A1, 2003 ; US 20030216446 A1 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |